Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells

Salida Mirzoeva, Deuk Kim Nam, Karen Chiu, Carrie A. Franzen, Raymond Bergan, Jill C. Pelling

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Progression of cancer leads to hypoxic solid tumors that mount specific cell signaling responses to low oxygen conditions. An important objective of anti-cancer therapy is the development of new drugs that suppress hypoxic responses in solid tumors. Apigenin is a natural flavone that has been shown to have chemopreventive and/or anticancer properties against a number of tumor types. However, the mechanisms underlying apigenin's chemopreventive properties are not yet completely understood. In this study, we have investigated the effects of apigenin on expression of hypoxia-inducible factor-1 (HIF-1) in human metastatic prostate PC3-M cancer cells. We found that hypoxia induced a time-dependent increase in the level of HIF-1α subunit protein in PC3-M cells, and treatment with apigenin markedly decreased HIF-1α expression under both normoxic and hypoxic conditions. Further, apigenin prevented the activation of the HIF-1 downstream target gene vascular endothelial growth factor (VEGF). We then showed that apigenin inhibited expression of HIF-1α by reducing stability of the protein as well as by reducing the level of HIF-1α mRNA. We also found that apigenin inhibited Akt and GSK-3β phosphorylation in PC3-M cells. Further experiments demonstrated that constitutively active Akt blunted the effect of apigenin on HIF-1α expression. Taken together, our results identify apigenin as a bioflavonoid that inhibits hypoxia-activated pathways linked to cancer progression in human prostate cancer, in particular the PI3K/Akt/GSK-3 pathway. Further studies on the mechanism of action of apigenin will likely provide new insight into its applicability for pharmacologic targeting of HIF-1α for cancer therapeutic or chemopreventive purposes.

Original languageEnglish (US)
Pages (from-to)686-700
Number of pages15
JournalMolecular Carcinogenesis
Volume47
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Apigenin
Hypoxia-Inducible Factor 1
Flavonoids
Vascular Endothelial Growth Factor A
Prostate
Carcinoma
Neoplasms
Glycogen Synthase Kinase 3
flavone
Protein Stability
Protein Subunits
Phosphatidylinositol 3-Kinases
Prostatic Neoplasms
Phosphorylation
Oxygen

Keywords

  • Akt
  • Apigenin
  • Hypoxia
  • Hypoxia-inducible factor-1α
  • Prostate

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. / Mirzoeva, Salida; Nam, Deuk Kim; Chiu, Karen; Franzen, Carrie A.; Bergan, Raymond; Pelling, Jill C.

In: Molecular Carcinogenesis, Vol. 47, No. 9, 09.2008, p. 686-700.

Research output: Contribution to journalArticle

@article{c4636c35950b4e95b72374f1bf514b98,
title = "Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells",
abstract = "Progression of cancer leads to hypoxic solid tumors that mount specific cell signaling responses to low oxygen conditions. An important objective of anti-cancer therapy is the development of new drugs that suppress hypoxic responses in solid tumors. Apigenin is a natural flavone that has been shown to have chemopreventive and/or anticancer properties against a number of tumor types. However, the mechanisms underlying apigenin's chemopreventive properties are not yet completely understood. In this study, we have investigated the effects of apigenin on expression of hypoxia-inducible factor-1 (HIF-1) in human metastatic prostate PC3-M cancer cells. We found that hypoxia induced a time-dependent increase in the level of HIF-1α subunit protein in PC3-M cells, and treatment with apigenin markedly decreased HIF-1α expression under both normoxic and hypoxic conditions. Further, apigenin prevented the activation of the HIF-1 downstream target gene vascular endothelial growth factor (VEGF). We then showed that apigenin inhibited expression of HIF-1α by reducing stability of the protein as well as by reducing the level of HIF-1α mRNA. We also found that apigenin inhibited Akt and GSK-3β phosphorylation in PC3-M cells. Further experiments demonstrated that constitutively active Akt blunted the effect of apigenin on HIF-1α expression. Taken together, our results identify apigenin as a bioflavonoid that inhibits hypoxia-activated pathways linked to cancer progression in human prostate cancer, in particular the PI3K/Akt/GSK-3 pathway. Further studies on the mechanism of action of apigenin will likely provide new insight into its applicability for pharmacologic targeting of HIF-1α for cancer therapeutic or chemopreventive purposes.",
keywords = "Akt, Apigenin, Hypoxia, Hypoxia-inducible factor-1α, Prostate",
author = "Salida Mirzoeva and Nam, {Deuk Kim} and Karen Chiu and Franzen, {Carrie A.} and Raymond Bergan and Pelling, {Jill C.}",
year = "2008",
month = "9",
doi = "10.1002/mc.20421",
language = "English (US)",
volume = "47",
pages = "686--700",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells

AU - Mirzoeva, Salida

AU - Nam, Deuk Kim

AU - Chiu, Karen

AU - Franzen, Carrie A.

AU - Bergan, Raymond

AU - Pelling, Jill C.

PY - 2008/9

Y1 - 2008/9

N2 - Progression of cancer leads to hypoxic solid tumors that mount specific cell signaling responses to low oxygen conditions. An important objective of anti-cancer therapy is the development of new drugs that suppress hypoxic responses in solid tumors. Apigenin is a natural flavone that has been shown to have chemopreventive and/or anticancer properties against a number of tumor types. However, the mechanisms underlying apigenin's chemopreventive properties are not yet completely understood. In this study, we have investigated the effects of apigenin on expression of hypoxia-inducible factor-1 (HIF-1) in human metastatic prostate PC3-M cancer cells. We found that hypoxia induced a time-dependent increase in the level of HIF-1α subunit protein in PC3-M cells, and treatment with apigenin markedly decreased HIF-1α expression under both normoxic and hypoxic conditions. Further, apigenin prevented the activation of the HIF-1 downstream target gene vascular endothelial growth factor (VEGF). We then showed that apigenin inhibited expression of HIF-1α by reducing stability of the protein as well as by reducing the level of HIF-1α mRNA. We also found that apigenin inhibited Akt and GSK-3β phosphorylation in PC3-M cells. Further experiments demonstrated that constitutively active Akt blunted the effect of apigenin on HIF-1α expression. Taken together, our results identify apigenin as a bioflavonoid that inhibits hypoxia-activated pathways linked to cancer progression in human prostate cancer, in particular the PI3K/Akt/GSK-3 pathway. Further studies on the mechanism of action of apigenin will likely provide new insight into its applicability for pharmacologic targeting of HIF-1α for cancer therapeutic or chemopreventive purposes.

AB - Progression of cancer leads to hypoxic solid tumors that mount specific cell signaling responses to low oxygen conditions. An important objective of anti-cancer therapy is the development of new drugs that suppress hypoxic responses in solid tumors. Apigenin is a natural flavone that has been shown to have chemopreventive and/or anticancer properties against a number of tumor types. However, the mechanisms underlying apigenin's chemopreventive properties are not yet completely understood. In this study, we have investigated the effects of apigenin on expression of hypoxia-inducible factor-1 (HIF-1) in human metastatic prostate PC3-M cancer cells. We found that hypoxia induced a time-dependent increase in the level of HIF-1α subunit protein in PC3-M cells, and treatment with apigenin markedly decreased HIF-1α expression under both normoxic and hypoxic conditions. Further, apigenin prevented the activation of the HIF-1 downstream target gene vascular endothelial growth factor (VEGF). We then showed that apigenin inhibited expression of HIF-1α by reducing stability of the protein as well as by reducing the level of HIF-1α mRNA. We also found that apigenin inhibited Akt and GSK-3β phosphorylation in PC3-M cells. Further experiments demonstrated that constitutively active Akt blunted the effect of apigenin on HIF-1α expression. Taken together, our results identify apigenin as a bioflavonoid that inhibits hypoxia-activated pathways linked to cancer progression in human prostate cancer, in particular the PI3K/Akt/GSK-3 pathway. Further studies on the mechanism of action of apigenin will likely provide new insight into its applicability for pharmacologic targeting of HIF-1α for cancer therapeutic or chemopreventive purposes.

KW - Akt

KW - Apigenin

KW - Hypoxia

KW - Hypoxia-inducible factor-1α

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=50249087534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249087534&partnerID=8YFLogxK

U2 - 10.1002/mc.20421

DO - 10.1002/mc.20421

M3 - Article

VL - 47

SP - 686

EP - 700

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 9

ER -